Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human.  biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. 

Biotechnology

Life Sciences

Therapeutics

Kynexis

Kees Been

Lauren Cortellessa

Christer Köhler

Francis Mcmahon

Dennis Murphy

The Leadership Team at Kynexis is responsible for defining and steering the strategic vision and operational direction of the company. They guide the development and commercialization of KYN-5356, ensuring alignment with the company’s mission to advance precision therapeutics for brain diseases. The team oversees critical functions including clinical development, business strategy, and medical affairs, and ensures effective company-wide execution and stakeholder engagement.

Leadership Team

The Clinical Development Team at Kynexis is responsible for designing and overseeing clinical trials to evaluate the safety and efficacy of KYN-5356, the company’s lead candidate for treating cognitive impairment associated with schizophrenia. This multidisciplinary team collaborates on regulatory submissions, manages the logistics of clinical trial operations, and integrates translational science insights to optimize patient stratification using biomarker data. Their goal is to ensure that Kynexis advances its innovative therapeutic approach while adhering to regulatory standards and industry best practices.

Kynexis

Org chart

Teams

Leadership Team

Clinical Development Team

Offices

Kynexis

Org chart

Teams

Leadership Team

Clinical Development Team

Offices

Related companies